bioAffinity Technologies, Inc. (BIAF) vs DermTech, Inc. (DMTKQ)

bioAffinity Technologies, Inc. and DermTech, Inc. are both Diagnostics & Research companies. bioAffinity Technologies, Inc. is the larger, with a market value of $9.0M against $3.3M — 2.7× the size. DermTech, Inc. grew revenue faster over the last twelve months: 9.71% against −23.2%. bioAffinity Technologies, Inc. has the higher net margin (−257.3% vs −572.2%) and the higher return on invested capital (−408.7% vs −5,493.5%). Across the 15 metrics below, DermTech, Inc. leads on 9 and bioAffinity Technologies, Inc. on 6.

Valuation

Metric BIAF DMTKQ Diagnostics & Research median
P/E n/m n/m 33.95
P/S 0.47 n/m 4.87
P/B 0.73 n/m 3.12
Price to free cash flow n/m n/m 34.02
EV/EBITDA n/m 0.45 25.20
EV/Sales 0.15 (2.49) 5.66
Earnings yield (1,380.14%) 0.00% (1.75%)
Free cash flow yield (418.18%) 0.00% (0.13%)

Profitability

Metric BIAF DMTKQ Diagnostics & Research median
Gross margin 34.61% 8.51% 50.89%
Operating margin (209.82%) (588.62%) (8.57%)
Net margin (257.33%) (572.19%) (6.37%)
Free cash flow margin (195.90%) (460.10%) 0.00%
Return on equity (1,860.15%) (121.75%) (2.92%)
Return on assets (245.51%) (64.00%) (6.71%)
Return on invested capital (408.67%) (5,493.45%) 0.00%

Growth

Metric BIAF DMTKQ Diagnostics & Research median
Revenue growth (TTM) (23.18%) 9.71% 7.69%
EPS growth (last fiscal year) 61.55% 20.36% —
Revenue growth, 5-year CAGR — 44.33% 7.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BIAF DMTKQ Diagnostics & Research median
Debt to equity 0.15 0.00 0.11
Current ratio 1.44 3.53 2.02
Net debt to EBITDA 0.57 0.57 0.78

Dividend

Metric BIAF DMTKQ Diagnostics & Research median
Dividend yield — — 0.70%
Payout ratio — 0.00 0.00

Size

Metric BIAF DMTKQ Diagnostics & Research median
Market cap 9.00m 3.29m 2.56b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack